Indeed, in breast cancer patients increasing ctDNA levels are associated with inferior survival and increased risk of recurrence, while one study reported 96% of EGFR-mutated colorectal or NSCLCs demonstrated a reduction in ctDNA plasma levels after initiation of targeted therapy (21). This evidence concerns the gene EGFR and breast carcinoma.